We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00413712
First Posted: December 20, 2006
Last Update Posted: February 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Singapore General Hospital
  Purpose
The purpose of this study is to determine the efficacy and effectiveness of calcium channel blockers and adenosine in the treatment of Supraventricular Tachycardia.

Condition Intervention Phase
Supraventricular Tachycardia Drug: Calcium Channel Blocker & Adenosine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.

Resource links provided by NLM:


Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:
  • Conversion to the sinus rhythm.

Secondary Outcome Measures:
  • Recurrence of SVT
  • Stability of vital signs

Estimated Enrollment: 206
Study Start Date: January 1997
Estimated Study Completion Date: March 2001
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • More than 10 years old
  • Electrocardiographic diagnosis of SVT
  • SVT not converted by the vagal manoeuvres

Exclusion Criteria:

  • Signs of impaired cerebral perfusion
  • Signs of pulmonary oedema
  • Subsequent diagnosis of other types of arrythmias rather than SVT
  • pregnancy by history
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00413712


Locations
Singapore
Singapore General Hospital
Singapore, Singapore, 62223322
Sponsors and Collaborators
Singapore General Hospital
Investigators
Principal Investigator: Lim S Han, MBBS,FRCS Department of Emergency Medicine, Singapore General Hospital
  More Information

Publications:

Responsible Party: Singapore General Hospital
ClinicalTrials.gov Identifier: NCT00413712     History of Changes
Other Study ID Numbers: IRB18/1997
First Submitted: December 19, 2006
First Posted: December 20, 2006
Last Update Posted: February 10, 2017
Last Verified: February 2017

Keywords provided by Singapore General Hospital:
Supraventricular Tachycardia
Calcium Channel Blockers
Verapamil
Diltiazem
Adenosine

Additional relevant MeSH terms:
Emergencies
Tachycardia
Tachycardia, Supraventricular
Disease Attributes
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Calcium, Dietary
Adenosine
Calcium Channel Blockers
Bone Density Conservation Agents
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Membrane Transport Modulators